"Mannkind (Nasdaq: MNKD ) ** (12.2%) Idenix Pharmaceuticals (Nasdaq: IDIX ) * (11.5%)

The markets jumped 158 points on Friday, or 1.2%, so stocks that went down by even larger percentages are pretty big deals.

That's gonna leave a mark
The drop in share value of biopharmaceutical drug developer Mannkind was the continued fallout over its decision to massively dilute shareholders. The stock lost a third of its value last week after the company announced plans to offer $50 million in stock and up to $161 million in debt with the stock portion of the deal, including a warrant to purchase part of a second share.

Mannkind is hoping to bring its inhaled insulin therapy Afrezza to market, but has run into resistance from the FDA, which has concerns over the company's switch to the Dreamboat inhaler. However, even if Afrezza makes it to market, there are still questions over its potential. Pfizer's Exubera was a commercial flop and ended development of the drug. Both Novo Nordisk (NYSE: NVO ) and Eli Lilly (NYSE: LLY ) subsequently abandoned plans for their own inhaled insulin treatments as a result, sticking with their tried-and-true insulin offerings.

Mannkind proposed a $370 million debt offering last September and surprised everyone with the latest offering, which suggests the company is having difficulties and is quickly running out of cash. Despite the�FDA�giving the biopharma the�go-ahead for two clinical studies, unless it quickly partners with someone, a development most people seem not to expect, then the company is likely to continue spiraling down.

Although 82% of the CAPS members rating the biopharma believe it can still beat the market averages going forward, the low, two-star rating they've assigned it suggests they also think there are better places for your money. Add Mannkind to your Watchlist to see if it can rebound from management's dilutive ways."

http://best-stocks-broker.blogspot.com/2012/05/why-did-my-stock-just-die.html